Houston, TX, Jun 02, 2022 — NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M…
C2i Genomics Expands AI-Powered Cancer Detection and Monitoring Capabilities in US and China Through Partnership with NuProbe
The deal will combine C2i’s AI-driven cancer intelligence platform with NuProbe’s advanced sequencing technology to power pharma and diagnostic services.
NuProbe will integrate QASeq and BDA technologies with Bionano’s Saphyr system for research and product development in the fields of reproductive health and oncology liquid biopsies.
The lead investors for this financing round are BioTrack Capital and Yonghua Capital. The proceeds will be used to expand the commercial team in both the US and China, develop new NGS products, and file for regulatory approval in China for NuProbe’s clinical products.
NuProbe and Weigao Group will apply NuProbe’s proprietary Blocker Displacement Amplification (BDA) technology to developing a liquid biopsy NGS panel for non-small cell lung cancer (NSCLC). The product will be compatible with the desktop NGS instruments, and the companies plan to later apply for in vitro diagnostic (IVD) registration with NMPA, China’s equivalent of FDA.
NuProbe Announced New Clinical Advisory Board Members from Yale and MD Anderson, Launched NGS Multi-gene Panels
Two additional world-renowned oncologists will join NuProbe’s clinical advisory board: Amir A. Jazaeri, M.D., from the University of Texas MD Anderson Cancer Center and Abhijit Patel, M.D., Ph.D., from Yale University School of Medicine
NuProbe Announces Strategic Collaboration with QIAGEN, Completes Multiple CE IVD Product Registrations
NuProbe and QIAGEN will collaborate to develop next-generation sequencing (NGS)-based cancer diagnostic tests for non-invasive liquid biopsy. NuProbe and QIAGEN will explore integrating their two amplicon-based enrichment and sequencing technologies: NuProbe’s proprietary Blocker Displacement Amplification (BDA) technology and QIAGEN’s Single Primer Extension (SPE) technology,
Oxford Nanopore has licensed NuProbe’s Blocker Displacement Amplification technology globally for undisclosed consideration. The technology combination offers the potential to combine Oxford Nanopore sequencing, which offers real-time, rapid turnaround, scalable sequencing of any length DNA or RNA fragments, with the NuProbe technique to enable greater detection sensitivities and quantification of somatic mutations at less than 5% allele frequency.
NuProbe Global and CarrierGene Biotech Co. Ltd. Announced Completion of Merger, Appointed Yingshuang Chai as CEO
NuProbe Global and CarrierGene Biotech Co. Ltd. (Suzhou, China) announced the successful completion of their recent merger and integration. The new company will operate under the English brand NuProbe Global and the Chinese brand阅尔 (Yue Er).
George M. Church, Ph.D., Professor of Genetics at Harvard Medical School, and David R. Walt, Ph.D., Professor of Pathology at Harvard Medical School will form NuProbe’s Scientific Advisory Board.